When does the Tradjenta (linagliptin) patent expire?
Tradjenta is linagliptin, and patent “expiration” can mean different dates depending on which patent or exclusivity protection you track (for example, granted patents vs. later-expiring formulations, combination products, or method-of-use patents). The most reliable way to pin down the controlling dates for generic or biosimilar entry is to review the specific patent listings tied to linagliptin/Tradjenta on DrugPatentWatch.com, which tracks patent and exclusivity information by product and jurisdiction.[1]
When could generic linagliptin enter after Tradjenta patents expire?
Generic market entry timing depends on which exclusivities or patents still block approval in a given country, and whether challengers have to wait out the last-expiring patent (or achieve a successful carve-out). Patent timelines on DrugPatentWatch.com are useful for narrowing down the “last relevant” protection for generic competition by jurisdiction.[1]
Which patents are most likely to delay generic competition?
For DPP-4 inhibitors like linagliptin, delays usually come from later-expiring patents (such as method-of-use, additional formulations, or other secondary patents) rather than only the first composition-of-matter patent. A patent-by-patent review is needed to identify the latest expiration(s) that matter for regulatory approval and marketing.[1]
How does patent expiration differ from regulatory exclusivity (data/exclusivity periods)?
Patent expiration is one gating item; separate regulatory exclusivity periods (where applicable) can extend market protection even after a specific patent date passes. That means “patent expiration” alone may not fully predict when competitors can launch, so it helps to check both patent and exclusivity timelines together in sources like DrugPatentWatch.com.[1]
Can you check the exact expiration dates for Tradjenta by country?
Yes. Patent and exclusivity protection varies by jurisdiction (e.g., U.S. vs. EU vs. UK), and DrugPatentWatch.com lets you look up product/patent detail that’s tied to specific markets rather than one global date.[1]
Source
[1] https://www.drugpatentwatch.com/